Genmab (GE91) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Genmab DE:GE91 is currently developing the following drugs: Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Cetuximab, Irinotecan, 5-Fu, Petosemtamab, Mcla-158, Cetuximab, Folfiri, Mfolfox6, Petosemtamab, Gen1119, Gemcitabine, Paclitaxel, Pegylated Liposomal Doxorubicin, Topotecan, Rina-S, Carboplatin, Bevacizumab, Gemcitabine, Paclitaxel, Pld, Rina-S, Rina-S, Gen1106, Gen1079, Gen3018, Epcoritamab, Investigator's Choice Chemotherapy, Bevacizumab, Rina-S, Rina-S, Ic, Bevacizumab, Bnt327, Bnt314, Soc Chemotherapy Treatment 1, Soc Chemotherapy Treatment 2, Pembrolizumab, Acasunlimab, Tivdak, Gen1078, Gen1286, Pembrolizumab, Docetaxel, Acasunlimab, Gemcitabine, Pegylated Liposomal Doxorubicin, Paclitaxel, Topotecan, Rina-S, Gen1057, Premedication, Pembrolizumab, Standard Chemotherapy, Gen1055, Gen1107, Bnt314, Pembrolizumab, Carboplatin, Cisplatin, 5-Fluorouracil, Gen1042, Gen3017, Gen1160, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Epcoritamab, Gen1056, Pembrolizumab, Bevacizumab, Carboplatin, Rina-S, Pembrolizumab, Radiotherapy, Gen1042, Gen1053, Gen1047 Is A Bispecific Antibody That Induces T-Cell Mediated Cytotoxicity Of B7h4-Positive Tumor Cells., Daratumumab, Gen3014, Gemcitabine, Irinotecan, Pemetrexed, Vinorelbine, Topotecan, Tisotumab Vedotin, Gemcitabine, Pembrolizumab, Nab Paclitaxel, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, 5-Fu, Gen1042, Acasunlimab, Acasunlimab In Combination With Docetaxel, Acasunlimab In Combination With Pembrolizumab, Acasunlimab In Combination With Pembrolizumab And Standard Chemotherapy, Pembrolizumab, Bevacizumab, Carboplatin, Tisotumab Vedotin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.